Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CC-97489 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part 1 | EXPERIMENTAL | - |
| Part 2 | EXPERIMENTAL | - |
| Part 3 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| CC-97489 | DRUG | Specified dose on specified days |
| [18F]T-401 | DRUG | Specified dose on specified days |
| [11C]MK-3168 | DRUG | Specified dose on specified days |
Inclusion Criteria: * Has a Body Mass Index (BMI) of 18.0 to 33.0 kg/m\^2, inclusive. BMI = weight (kg)/(height \[m\])\^2 * Must be healthy based on medical history, physical examination (PE), clinical laboratory test results, vital signs, and 12-lead electrocardiogram (ECG) at screening and check-...
CC-97489 is an investigational small molecule being studied in healthy volunteers. It is currently in Phase 1 clinical development, with a completed trial that evaluated its effects on enzyme availability in the central nervous system using positron emission tomography (PET) imaging.
CC-97489 is being developed by Bristol-Myers Squibb Company, which trades under the ticker symbol BMY. The company is conducting clinical research on this investigational small molecule.
CC-97489 is in Phase 1 clinical development. The drug is investigational and has not been approved by regulatory authorities. Its Phase 1 trial has been completed, and it is not currently in active clinical trials.
CC-97489 has one completed Phase 1 trial, NCT05065541, which enrolled 32 healthy participants in Belgium. The study used PET imaging to evaluate enzyme availability in the central nervous system before and after CC-97489 administration.
CC-97489 is not FDA approved. It is an investigational drug in Phase 1 clinical development. The completed trial in healthy volunteers was a controlled study, but the drug has not yet progressed to later-stage trials or regulatory approval.